Clinical Trials Browser

Phase 2 × Kidney Diseases × Clear all

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT04009668 2024-10-30

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Phase 2 Completed

7 enrolled 12 charts

Genitourinary

Macular dystrophy, corneal type 1, Glomerulosclerosis, Focal Segmental, Kidney Diseases, Nephrosis, Lipoid, Nephrotic Syndrome

NCT03960437 2023-09-21

Parsabiv-MBD

Phase 2 Completed

22 enrolled 14 charts

GenitourinaryHead & Neck

Bone Diseases, Hyperparathyroidism, Kidney Diseases, Neoplasm Metastasis, Chronic Kidney Disease-Mineral and Bone Disorder, Vascular Calcification

NCT00854620 2015-06-19

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Phase 2 Completed

9 enrolled 3 charts

Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms

NCT00540904 2014-03-03

Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate

Phase 2 Completed

27 enrolled

Genitourinary

Kidney Diseases

Clinical Trials

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Parsabiv-MBD

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate